Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Prevention of Antibody-Mediated Rejection in Sensitized Deceased Donor Kidney Transplant Recipients
2010-019631-35Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in humoral rejection, sponsored by Alexion Pharmaceuticals. Primary endpoint: Primary: Safety and potential efficacy of eculizumab to prevent antibody-mediated rejection. Started Dec 2011; status: completed.
02
Drugs
eculizumab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2010-019631-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019631-35.